Q-omics provides the consensus-scored RIPOR2 profile across patient tissues and cancer cell-line models. RIPOR2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RIPOR2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, RIPOR2 RNA expression shows 19,561 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where RIPOR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIPOR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIPOR2 survival associations across molecular data types. RIPOR2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIPOR2 RNA expression–survival associations across cancer types. High RIPOR2 expression shows unfavorable associations in UVM, but favorable associations in KIRC, HNSC, CESC, LUAD and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RIPOR2 RNA expression.
This table summarizes RIPOR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RIPOR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIPOR2 shows lower tumor expression in KICH, LUAD, COAD, BLCA and UCEC and higher tumor expression in KIRC. The KICH box plot shows higher RIPOR2 RNA expression in normal versus tumor tissue (log2 FC = −1.625, t-test p < 0.001).
This table shows molecular features associated with RIPOR2 in patient tissues and cancer cell lines. In patient samples, RIPOR2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RIPOR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
